تحميل...
A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma
Even though the prognosis of patients with multiple myeloma is continuing to improve, all patients eventually develop relapsed refractory disease. Several novel therapeutics have been developed in the last few years including the second-generation proteasome inhibitor carfilzomib which has been appr...
محفوظ في:
| الحاوية / القاعدة: | Ther Adv Hematol |
|---|---|
| المؤلفون الرئيسيون: | , , , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
SAGE Publications
2016
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5089326/ https://ncbi.nlm.nih.gov/pubmed/27904737 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716667275 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|